Patient Information: Summary of Product Characteristics
Everolimus Ethypharm 10 mgEFG tablets
Read the entire summary carefully before starting to take this medication, as it contains important information for you.
Summary of Product Characteristics
Everolimus Ethypharm is a cancer medication that contains the active substance everolimus. Everolimus reduces blood supply to the tumor and delays the growth and spread of cancer cells.
Everolimus Ethypharm is used to treat adult patients with:
Everolimus Ethypharm will only be prescribed by a doctor with experience in cancer treatment. Follow your doctor's instructions carefully. They may be different from the general information contained in this summary. If you have questions about Everolimus Ethypharm or why you have been prescribed this medication, consult your doctor.
Do not take Everolimus Ethypharm
If you think you may be allergic, consult your doctor.
Warnings and precautions
Consult your doctor before starting to take Everolimus Ethypharm:
Everolimus Ethypharm may also:
Tell your doctor if you are scheduled to receive radiation therapy soon or if you have received radiation therapy in the past.
Tell your doctorif you experience these symptoms.
During treatment, you will undergo periodic blood tests. These tests will determine the number of cells in the blood (white blood cells, red blood cells, and platelets) to check if everolimus is having an unwanted effect on these cells. You will also undergo blood tests to monitor kidney function (creatinine levels), liver function (transaminase levels), and blood sugar and cholesterol levels. These tests are performed because they may be affected by treatment with everolimus.
Children and adolescents
Everolimus Ethypharm should not be administered to children or adolescents (under 18 years of age).
Other medications and Everolimus Ethypharm
Everolimus Ethypharm may affect how other medications work. If you are taking other medications at the same time as Everolimus Ethypharm, your doctor may change the dose of Everolimus Ethypharm or the other medications.
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
The following may increase the risk of side effects with everolimus:
The following may reduce the effectiveness of everolimus:
Use of these medications should be avoided during treatment with everolimus. If you are taking any of them, your doctor may prescribe a different medication or change your dose of everolimus.
Taking Everolimus Ethypharm with food and drinks
Do not take grapefruit or grapefruit juice while taking Everolimus Ethypharm. It may increase the amount of Everolimus Ethypharm in the blood, possibly to a harmful level.
Pregnancy, breastfeeding, and fertility
Pregnancy
Everolimus may cause harm to the fetus and is not recommended during pregnancy. Inform your doctor if you are pregnant or think you may be. Your doctor will discuss with you whether you should take this medication during pregnancy.
Women who may become pregnant should use a highly effective contraceptive method during treatment and up to 8 weeks after finishing treatment. If, despite these measures, you think you may be pregnant, consult your doctor beforetaking more of this medication.
Breastfeeding
Everolimus may cause harm to the breastfed baby. Do not breastfeed during treatment and for 2 weeks after the last dose of everolimus. Inform your doctor if you are breastfeeding.
Female fertility
In some patients treated with Everolimus Ethypharm, absence of menstrual periods (amenorrhea) has been observed.
Everolimus may have an impact on female fertility. Inform your doctor if you want to have children.
Male fertility
Everolimus may affect male fertility. Consult your doctor if you want to be a father.
Driving and using machines
If you feel abnormally tired (fatigue is a very common side effect), be especially careful when driving or using machines.
Everolimus Ethypharm contains lactose
This medication contains lactose (milk sugar). If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow your doctor's or pharmacist's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
The recommended dose is 10 mg, once a day. Your doctor will inform you how many Everolimus Ethypharm tablets to take.
If you have liver problems, your doctor may start treatment with a lower dose of Everolimus Ethypharm (2.5; 5; or 7.5 mg per day).
If you experience side effects while taking Everolimus Ethypharm (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period or permanently.
Take Everolimus Ethypharm once a day, at about the same time, always with food or always without food.
Swallow the tablet(s) whole with a glass of water. Do not chew or crush the tablets.
If you take more Everolimus Ethypharm than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (Tel. 91 562 04 20) indicating the medication and the amount ingested.
If you forget to take Everolimus Ethypharm
If you miss a dose, take the next dose at the scheduled time. Do not take a double dose to make up for missed doses.
If you stop taking Everolimus Ethypharm
Do not stop taking Everolimus Ethypharm unless your doctor tells you to.
If you have any further questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP treatment with everolimus and seek immediate medical help if you experience any of the following signs of an allergic reaction:
Severe adverse effects of everolimus include:
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
potential signs of pulmonary embolism, a situation that occurs when one or more arteries in the lungs are blocked)
Rare(may affect up to 1 in 1,000 people)
If you experience any of these adverse effects, inform your doctor immediately as they could have fatal consequences.
Other possible adverse effects of everolimus include:
Very Common(may affect more than 1 in 10 people)
low red blood cell count (anemia)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency Not Known(cannot be estimated from the available data)
If these adverse reactions worsen, inform your doctor and/or pharmacist. Most adverse effects are mild to moderate and usually disappear if treatment is interrupted for a few days.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency's website: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and blister. The expiration date is the last day of the month indicated.
This medicine does not require any special storage temperature
Store in the original packaging to protect it from light.
Open the blister just before taking the tablets.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Medicines should not be disposed of via wastewater or household waste. Return the packaging and any unused medicine to the pharmacy's SIGRE point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Everolimus Ethypharm
Each Everolimus Ethypharm tablet contains 2.5 mg of everolimus.
Appearance of the Product and Package Contents
Everolimus Ethypharm 2.5 mg tablets are oblong, white to off-white, 9.6 x 4.5 mm. They are marked with "E" on one side and "2.5" on the other.
Everolimus Ethypharm 2.5 mg is available in packs containing 30 or 90 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Ethypharm
194 Bureaux de la Colline – Bâtiment D
92213 Saint-Cloud cedex
France
Manufacturer
Ethypharm
Chemin de la Poudrière
76120 Grand Quevilly
France
Ethypharm
Z.I. de Saint Arnoult
28170 Châteauneuf en Thymerais
France
You can request more information about this medicine from the local representative of the marketing authorization holder:
ALTAN PHARMACEUTICALS S.A.
C/Colquide, Nº 6, Portal 2, 1ª planta, Oficina F. Edificio Prisma
Las Rozas (Madrid)
28230 Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Sweden: | Everolimus Ethypharm 2.5 mg, tablets |
Austria: Germany: | Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm 2.5 mg, tablets |
Denmark: Italy: | Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm |
Finland: Netherlands: Norway: Portugal: | Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm Everolimus Ethypharm 2.5 mg, tablets |
Spain: | Everolimus Ethypharm 2.5 mg, tablets EFG |
United Kingdom: | Everolimus Ethypharm 2.5 mg, tablets |
Date of the last revision of this leaflet 04/2023.
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EVEROLIMUS ETHYPHARM 10 mg TABLETS – subject to medical assessment and local rules.